

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

14<sup>th</sup> September, 2017

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

Kind Attn: General Manager-DCS

Scrip Code: 533543

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Kind Attn: Head- Listing

Symbol: BROOKS

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 1<sup>st</sup> quarter ended 30<sup>th</sup> June, 2017. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

This is for your information and record.

Thanking You,


Yours faithfully

For **BROOKS LABORATORIES LIMITED**

  
**(Rajesh Mahajan)**  
Managing Director

DIN No. 02000634

Encl.: As Stated Above



**BROOKS LABORATORIES LIMITED**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net,

Website: www.brookslabs.net

Tel No : +91 1795 654001/02/03,

Fax No : +91 1795 236936

**Statement of Unaudited Financial Results for the Quarter June 30, 2017**

(Rs. In Lakhs)

Particulars	Quarter ended	
	30.06.2017 (Unaudited)	30.06.2016 (Unaudited)
<b>1. INCOME</b>		
a. Revenue from Operations	834.80	1,540.88
b. Other Income	3.48	4.00
<b>Total Income</b>	<b>838.28</b>	<b>1,544.88</b>
<b>2. Expenses</b>		
a. Cost of Materials consumed	593.51	823.94
b. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	(98.53)	63.60
c. Excise Duty on Sales	119.27	-
d. Employee benefits expenses	254.95	193.42
e. Finance costs	45.53	19.29
f. Depreciation & amortizations expenses	156.76	30.34
g. Other Expenses	310.11	170.21
<b>Total Expenses (a to g)</b>	<b>1,381.60</b>	<b>1,300.80</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>(543.32)</b>	<b>244.08</b>
4. Exceptional Items	-	-
<b>5. Profit / (Loss) before tax (3 - 4)</b>	<b>(543.32)</b>	<b>244.08</b>
<b>6. Tax expense</b>		
Current Tax	-	49.93
Deferred Tax	44.36	30.76
<b>7. Net Profit / (Loss) after tax (5 - 6)</b>	<b>(587.68)</b>	<b>163.39</b>
<b>8. Other Comprehensive Income</b>		
Items that will not be reclassified into Profit or Loss		
Actuarial loss on Defined Benefit plans (net of tax).	0.01	0.52
<b>9. Total Comprehensive Income for the year (after tax) (7 + 8)</b>	<b>(587.67)</b>	<b>163.91</b>
<b>10. Earnings per share of Re. 10/- each (Basic and Diluted)</b>		
(a) before extraordinary items (not annualised)	(3.63)	1.01
(b) after extraordinary items (not annualised)	(3.63)	1.01
See accompanying Notes to the Financial Results		



For Brooks Laboratories Ltd.

Managing Director

DIN: 02000634

### Notes to the Financial Results:-

1. The Financial Results of the Company for the quarter ended June 30, 2017 have been reviewed by the Audit committee and taken on record by the Board of Directors at its meeting held on September 14, 2017.
2. The Statutory Auditors have carried out Limited Review of the Financial Results of the Company for the quarter ended June 30, 2017.
3. The Ind-AS compliant corresponding figures in the previous year have not been subject to review audit. However, the Company's management has exercised due diligence to ensure that the financial results provide fair view of its affairs.
4. The Company adopted Indian Accounting Standards ("Ind-AS") from April 1, 2017 and accordingly the financial results of all periods presented have been prepared in accordance with the recognition and measurement principles laid down in the Ind-AS-34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. There is a possibility that this quarter financial results may require adjustment before constituting the final Ind-AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirement arising from new or revised standards or interpretations issued by Ministry of Corporate Affairs to changes in the use of one or more optional exemptions from full retrospective application of certain Ind-AS permitted under Ind-AS 101.
5. The Statement does not include Ind-AS compliant results for the preceding quarter and year ended March 31, 2017 as it is not mandatory as per SEBI Circular dated July 05, 2016.
6. The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS – 108 in this regard are not applicable.
7. Reconciliation of Net Profit and Total Comprehensive Income on account of transition from the previous Indian GAAP to Ind-AS for the Quarter ended June 30, 2016 is as under:

(Rs. In Lakhs)

Sr. No.	Particulars	For the Quarter ended June 30, 2016
	<b>Net Profit as per Indian GAAP</b>	<b>163.91</b>
	Benefit / (Charge)	
I	Actuarial Loss on Defined Benefit Plans reclassified to Other Comprehensive Income	(0.80)
III	Deferred Tax impact on above adjustments	0.28
	<b>Net Profit for the Quarter (as per Ind-AS)</b>	<b>163.38</b>
	<b>Other Comprehensive Income</b>	
	Actuarial Loss on Defined Benefit Plans (net of tax)	0.52
	<b>Total Profit including Comprehensive Income</b>	<b>163.91</b>



For Brooks Laboratories Ltd.

  
Managing Director

DIN: 02000634

8. Comparative financial information of the quarter ended June 30, 2016 have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current quarter.

Dated: - September 14, 2017

Place: - Mumbai



For BROOKS LABORATORIES LIMITED

**Rajesh Mahajan**  
Managing Director  
(DIN 02000634)

# **SGCO & Co. LLP**

Chartered Accountants

## **Independent Auditor's Review Report On Interim Financial Results**

### **The Board of Directors**

### **Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Brooks Laboratories Limited (The "Company"), for the quarter ended June 30, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rule issued thereunder and other accounting principles generally accepted in India. Further, the Management is also responsible to ensure that the accounting policies used in preparation of the Company's opening unaudited Balance Sheet as at April 01, 2016 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement
5. We draw attention to the following matters :
  - a. Note 4 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2017, and accordingly, the Statement has prepared by the Company's Management in compliance with Ind AS.

4A, Kaledonia-HDIL,  
2<sup>nd</sup> Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069. India

Tel.: +91 22 6625 6363  
Fax: +91 22 6625 6364  
E-mail: info@sgco.co.in  
www.sgco.co.in



**SGCO & Co. LLP**  
Chartered Accountants

- b. We were neither engaged to review, nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended on June 30, 2016 and accordingly, we do not express any conclusion on the results in the Statement for the quarter ended June 30, 2016. As set out in Note 3 to the Statement, these figures have been furnished by the Management.

Our conclusion is not qualified in respect of these matters.

**For S.G.C.O & Co. LLP**

Chartered Accountants

**Firm Reg. No 112081W/W100184**

  
**Suresh Murarka**  
Partner  
**Mem No.: 044739**



Place : Mumbai

Date : 14<sup>th</sup> September , 2017